Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
For one of its customers IQVIA is looking to recruit a GP Business Developer (omnichannel) within the domain of Women’s Health. This national function combines field (majority) and office-based work and and plays a key part